SunTrust Downgrades Intra-Cellular Therapies (ITCI) to Neutral

September 29, 2016 6:53 AM EDT
Get Alerts ITCI Hot Sheet
Price: $12.20 --0%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 50 | New: 20
Trade ITCI Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

SunTrust Robinson Humphrey downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Buy to Neutral with a price target of $15.00 (from $60.00).

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $42.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades

Related Entities

The Children's Investment Fund (TCI), SunTrust Robinson Humphrey

Add Your Comment